BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Valuation & Earnings
This table compares BioCryst Pharmaceuticals and Compass Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCryst Pharmaceuticals | $874.84 million | 2.44 | $263.86 million | ($1.50) | -5.57 |
| Compass Therapeutics | $850,000.00 | 198.63 | -$66.49 million | ($0.40) | -2.34 |
Institutional & Insider Ownership
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares BioCryst Pharmaceuticals and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCryst Pharmaceuticals | -40.90% | -86.89% | 66.37% |
| Compass Therapeutics | N/A | -38.71% | -34.72% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and Compass Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCryst Pharmaceuticals | 1 | 4 | 7 | 0 | 2.50 |
| Compass Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
BioCryst Pharmaceuticals presently has a consensus price target of $20.50, suggesting a potential upside of 145.22%. Compass Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 993.33%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than BioCryst Pharmaceuticals.
Risk & Volatility
BioCryst Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Summary
Compass Therapeutics beats BioCryst Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
